A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination With Palbociclib (Doublet) and With Palbociclib and Sasanlimab (Triplet) in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Latest Information Update: 11 Sep 2024
At a glance
- Drugs NKT 2152 (Primary) ; Palbociclib (Primary) ; Sasanlimab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors NiKang Therapeutics
- 10 Aug 2023 Status changed from not yet recruiting to recruiting.
- 06 Jul 2023 Status changed from planning to not yet recruiting.
- 09 Dec 2021 New trial record